SLENYTO
NEUROLOGY - New medicinal product
Opinions on drugs -
Posted on
Nov 22 2019
Reason for request
Inscription
-
SLENYTO has been granted a marketing authorisation for the treatment of insomnia in children and adolescents aged from 2 to 18 years with autism spectrum disorder (ASD) and/or Smith-Magenis syndrome, where sleep hygiene measures have been insufficient.
-
The superiority of melatonin LP over the placebo has been demonstrated on the improvement in total sleep time at 13 weeks with a moderate effect size: +32 minutes for patients with a total sleep time ofapproximately 7 hours 30 min.
Approved for non-hospital pharmacy reimbursement and for hospital treatment.
Clinical Benefit
Substantial |
The actual clinical benefit of SLENYTO is high |
Clinical Added Value
minor |
SLENYTO provides clinical added value** (CAV IV, minor) in the therapeutic strategy |
Documents
English version
Contact Us
Évaluation des médicaments